Immunomodulatory and Clinical Effects of Long-Term Low-Dose Macrolide Treatment of Chronic Rhinosinusitis with Nasal Polyposis

Perić, Aleksandar; Vojvodić, Danilo; Baletić, Nenad; Perić, Aneta; Miljanović, Olivera

doi:10.2478/v10011-010-0043-6

Cited by 2 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The treatment interval chosen in this study was based on the literature (35,36) . Furthermore, we noted the mid-range between the first appointment and surgery (usually 3 months at HC-UFMG).…”

Section: Discussionmentioning

confidence: 99%

Azithromycin for chronic eosinophilic rhinosinusitis with nasal polyp: a placebo-controlled trial

Oliveira

Guimaraes

Pêgas

et al. 2020

Rhin

View full text Add to dashboard Cite

BACKGROUND: Chronic eosinophilic rhinosinusitis with nasal polyps (CRSwNP eosinophilic) is characterised by the formation of benign and bilateral nasal polyps. We aimed to compare the effectiveness of azithromycin as an immunomodulator with the use of a placebo in patients presenting with CRSwNP concomitant with asthma and aspirin intolerance after 3 months of treatment and at a 1-year follow-up. METHODOLOGY: We performed a randomised, double-blind, placebo-controlled trial. Patients received 500 mg azithromycin orally three times/week for 12 weeks. Improvement was evaluated by staging, the Sino-Nasal Outcome Test (SNOT-22), and nasal polyp biopsy. Data collected at pretreatment and 3 months posttreatment were compared. Quality of life was evaluated at the 1-year follow-up. RESULTS: Twenty-seven and 21 patients were treated with azithromycin and a placebo, respectively. The medication was well tolerated overall. Twenty patients (74%) in the azithromycin group and three patients (14%) in the placebo group were not refer- red for surgery at the end of the 3-month treatment. Regarding subjective improvement, there was a median decrease only in the azithromycin group, and the between-group difference was significant. SNOT-22 improvement was maintained in the azithromy- cin group at the 1-year follow-up. CONCLUSIONS: Azithromycin could be considered a therapeutic option for patients presenting with CRSwNP concomitant with asthma and aspirin intolerance.

show abstract

Section: Discussionmentioning

confidence: 99%

Azithromycin for chronic eosinophilic rhinosinusitis with nasal polyp: a placebo-controlled trial

Oliveira

Guimaraes

Pêgas

et al. 2020

Rhin

View full text Add to dashboard Cite

show abstract

“…After SIT, the proportion of cells with oligoclonal proliferation was significantly increased, and this preferable expression of selected genes may be related to certain functions. The T cells in healthy individuals usually present polyclonal proliferation (17). Only after the stimulation by specific antigens the body generates clonal T cells as a response to the specific antigens.…”

Section: Discussionmentioning

confidence: 99%

Effects of Immunotherapy on the Distribution and Clonality of TCR Vγ and Vδ Subfamily T Cells in Allergic Rhinitis Patients

Yang¹,

Li²,

Wu³

et al. 2012

Journal of Medical Biochemistry

View full text Add to dashboard Cite

Summary: The aim of this study was to investigate the changes in the peripheral specific IgE level, distribution of TCR Vg and Vd subfamily T cells and mRNA expressions of TCR Vg I-III following specific immunotherapy (SIT) with house-dust-mite extract in allergic rhinitis (AR) patients. Ten AR patients undergoing SIT with house-dust-mite extract for 1 year were recruited. Quanti tative analysis of immunofluorescence was performed to detect the serum specific IgE (sIgE) level before and after SIT; RT-PCR-genescan analysis was employed to detect the mRNA expressions of TCR Vg (I-III) and Vd (1-8) in the peripheral mononuclear cells followed by analysis of T cell clonality. Real-time quantitative PCR was applied to detect the expressions of TCR Vg I-III genes. Ten healthy volunteers served as controls. For AR patients, SIT treatment could improve the symptoms, but the serum sIgE level was not markedly decreased. Before SIT, the expressions of TCR Vg I-III gene were similar between AR patients and controls (P>0.05) but markedly decreased after SIT in AR patients (P<0.05 in TCR VgI and VgII). The expressions of TCR Vd (1-8) before and after SIT were 5.3±0.82 and 4.9±0.57, respectively, and that in healthy controls was 5.2±1.40. Vd1, 2, 3 and 6 were the most common genes found in these patients. Significant difference in the TCR Vd6 subfamily T cells was found between the two groups. Polyclonal or biclonal proliferation was found in the T cells of patients before SIT and in healthy controls, but oligoclonal proliferation in only 1 subject before SIT. After SIT, the proportion of patients with oligoclonal proliferation of T cells (6/10) was markedly increased (P<0.05). SIT for 1 year could alter the expressions of TCR Vg I-III genes, the Kratak sadr`aj: Cilj ove studije bio je da se istra`e promene u nivou specifi~nog IgE u perifernoj krvi, distribuciji T }elija iz potporodice TCR Vg i Vd i ekspresiji TCR Vg I-III u mRNK posle specifi~ne imunoterapije (SIT) sa ekstraktom grinja iz ku}ne pra{ine kod pacijenata sa alergijskim rinitisom (AR). Uklju~eno je 10 pacijenata sa AR le~enih specifi~nom imunoterapijom sa ekstraktom grinja iz ku}ne pra{ine tokom 1 godine. Obavljena je kvantitativna analiza imunofluorescencijom kako bi se odredio nivo specifi~nog IgE (sIgE) u serumu pre i posle SIT; primenjena je RT-PCRgenescan analiza radi odre|ivanja ekspresije TCR Vg (I-III) i Vd (1-8) u mRNK u perifernim mononuklearnim }elijama posle ~ega je obavljena analiza klonalnosti T }elija. Kvantitativna PCR analiza u realnom vremenu sprovedena je kako bi se odredila ekspresija TCR Vg I-III gena. Deset zdravih dobrovoljaca slu`ilo je kao kontrolna grupa. Kod pacijenata sa AR, tretman SIT olak{ao je simptome, ali nivo sIgE u serumu nije se zna~ajno snizio. Pre SIT, ekspresija TCR Vg I-III gena bila je sli~na kod pacijenata sa AR i kontrolnih subjekata (P>0,05), ali se zna~ajno snizila posle SIT kod pacijenata sa AR (P>0,05 u TCR VgI i VgII). Ekspresija TCR Vd (1-8) pre i posle SIT bila je 5,3±0,82 i 4,9±0,57, a kod zdravih subjekata 5,2±1...

show abstract

Immunomodulatory and Clinical Effects of Long-Term Low-Dose Macrolide Treatment of Chronic Rhinosinusitis with Nasal Polyposis

Cited by 2 publications

References 19 publications

Azithromycin for chronic eosinophilic rhinosinusitis with nasal polyp: a placebo-controlled trial

Azithromycin for chronic eosinophilic rhinosinusitis with nasal polyp: a placebo-controlled trial

Effects of Immunotherapy on the Distribution and Clonality of TCR Vγ and Vδ Subfamily T Cells in Allergic Rhinitis Patients

Contact Info

Product

Resources

About